This Brain Cancer Awareness Month (May), The Kids’ Cancer Project is calling for discussion, awareness and funding of childhood brain cancer, the leading killer of Australian children by disease.
With research the only way towards a cure, The Kids’ Cancer Project is committed to funding a breadth of scientists and research projects that investigate childhood brain cancer and treatment options. With the effects of treatment posing different developmental challenges to children, the need for bespoke cancer research for children remains imperative.
As part of a new international clinical trial for a group of deadly brain tumours, Australian children will be the first in the world to access a new novel drug, Larotrectinib. Co-funded by The Kids Cancer Project, CONNECT-1903, is the first study to examine if Larotrectinib can be used in the treatment of children with newly diagnosed high-grade gliomas (HGG), a diagnosis approximately 40 to 50 Australian children receive each year.
Australian Principal Investigator Professor, Dr Nick Gottardo said, “At Perth Children’s Hospital, we are very excited to be the first centre in the world to offer our children access to this promising drug. It is vital that we offer this drug in the regulated setting of a clinical trial, so we can be confident about how well it is tolerated and its effectiveness in treating paediatric HGG.”
CEO of The Kids Cancer Project, Owen Finegan says, “We believe the only way to improve outcomes for kids with cancer is through advances in medical research. Each research project we fund is a step towards a world with less children suffering from cancer and less adults’ livings with the long-term effects of childhood cancer.”
Dr Raelene Endersby, a medical researcher whose career is dedicated to finding kinder, more effective treatments for children with brain cancer, shares her perspective, “We need people with the right expertise, both in the lab and in the clinic, and we need investment in research, equipment and people, and oversight from a regulatory perspective. Our goal is not just greater survival rates, but better quality of life for survivors, too.”
In a show of commitment to tackle the key issues around children’s brain cancer, The Kids’ Cancer Project, is hosting a Kids’ Brain Cancer 360 Live event led by Dr Nick Gottardo and Professor Brandon Wainwright, Co-Director of the Children’s Brain Cancer Centre. The event will take place on Wednesday 26 May between 3 PM and 5:30 PM in Melbourne.
CONNECT-1903 is a clinical trial designed by COllaborative Network for NEuro-oncology Clinical Trials (CONNECT), a recently established United States (U.S)-led consortium who are developing clinical trials for high-risk paediatric brain cancers by combining novel agents with traditional therapies. CONNECT-1903 is the first study to examine if a novel drug Larotrectinib can be used in the treatment of children with newly diagnosed HGG. As Larotrectinib targets tumours with a specific cancer-causing mutation (NTRK fusions), only children with this genetic change will be eligible for this trial (which can be up to 40% of children diagnosed with HGG in some age groups, such as babies and infants).
KIDS’ BRAIN CANCER 360 EVENT
On Wednesday 26 May 2021, Owen Finegan, CEO of The Kids’ Cancer Project will chair a workshop to discuss the current barriers around children’s brain cancer research. Invited guests include key note speakers Dr Nick Gottardo and Professor Brandon Wainwright along with other paediatric brain cancer researchers, frontline health care professionals, advocates and patient carers – all who will provide a 360 degree view of the issues faced by children diagnosed with brain cancer today. The goal of the session is to identify one major priority that will be addressed by the collaborative consort.
Source: The Kids Cancer Project